Search results for "FDA update"


 
Results 41 - 50 of about 98 for "FDA update".

Empagliflozin approved to treat type 2 diabetes | ACP Diabetes Monthly

Empagliflozin (Jardiance), a sodium glucose co-transporter 2 inhibitor, was recently approved to treat type 2 diabetes in addition to diet and exercise, the FDA announced last week.

New drug approved, meters recalled | ACP Diabetes Monthly

Dapaglifozin (Farxiga), a new medication to treat type 2 diabetes, was recently approved by the FDA for use along with diet and exercise.

New GLP-1 agonist approved | ACP Diabetes Monthly

A new glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide (Trulicity), was approved to treat type 2 diabetes, along with diet and exercise, the FDA recently announced.

Incretin mimetics' effects on pancreas under investigation | ACP Diabetes Monthly

The FDA is investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes.

New drugs approved for diabetes | ACP Diabetes Monthly

The first generic version of pioglitazone hydrochloride (Actos) and a new indication for ranibizumab injection (Lucentis) were recently announced by the FDA.

First drug in new class approved | ACP Diabetes Monthly

The FDA recently approved canaglifozin (Invokana) tablets to improve glycemic control in adults with type 2 diabetes, along with diet and exercise.

Another weight loss drug approved | ACP Diabetes Monthly

A combination of phentermine and topiramate extended-release (Qsymia) was recently approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic weight management.

Liraglutide gets new cardiovascular indication | ACP Diabetes Monthly

The FDA approved a new indication for liraglutide to reduce the risk of myocardial infarction, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Recall, warning, and a new generic drug | ACP Diabetes Monthly

Insulin cartridge holders were recalled, patients were warned about pre-owned test strips, and a generic form of rosiglitazone maleate and metformin hydrochloride was approved.

New GLP-1 receptor agonist approved | ACP Diabetes Monthly

Albiglutide (Tanzeum), a glucagon-like peptide-1 (GLP-1) receptor agonist, was recently approved by the FDA to treat type 2 diabetes in adults, along with diet and exercise.

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next